Literature DB >> 9038720

A human CD4+ T-cell line expresses functional CD64 (Fc gamma RI), CD32 (Fc gamma RII), and CD16 (Fc gamma RIII) receptors but these do not enhance the infectivity of HIV-1-IgG complexes.

L McLain1, N J Dimmock.   

Abstract

T cells do not generally express Fc receptors (FcRs). However, we report here that C8166 cells, a human CD4+ T lymphoblastoid cell line, widely used in research into the human immunodeficiency virus type 1 (HIV-1), expressed CD64 (Fc gamma RI), CD32 (Fc gamma RII), and CD16 (Fc gamma RIII) on the plasma membrane as shown by immunostaining with specific monoclonal antibody fragments. Another human CD4+ T lymphoblastoid cell line. H9, expressed none of these FcRs. C8166 cells bound monomeric normal rat serum IgG in a dose-dependent manner, and when saturated bound heat-complexed immunoglobulin G (IgG) also dose dependently. These observations are consistent with the presence on the C8166 T-cell line of both high- and low-affinity Fc gamma Rs. Fc gamma Rs are putative receptors for virus-IgG complexes, but in this study did not enhance infectivity of HIV-1 complexed with a human neutralizing mAb or three rat neutralizing mAbs. Virus complexed with a non-neutralizing mouse mAb was unable to infect cells using Fc gamma Rs as receptors after CD4 was blocked with a specific anti-CD4 mAb.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038720      PMCID: PMC1456708          DOI: 10.1046/j.1365-2567.1997.00116.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

Review 1.  Human antibody effector function.

Authors:  D R Burton; J M Woof
Journal:  Adv Immunol       Date:  1992       Impact factor: 3.543

2.  Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies.

Authors:  D M Morens; S B Halstead
Journal:  J Gen Virol       Date:  1990-12       Impact factor: 3.891

3.  AIDS. Do antibodies enhance the infection of cells by HIV?

Authors:  D P Bolognesi
Journal:  Nature       Date:  1989-08-10       Impact factor: 49.962

Review 4.  The occurrence, structural and functional properties of immunoglobulin Fc receptors on murine neoplastic cells.

Authors:  C Neauport-Sautes; M Daëron; J L Teillaud; U Blank; W H Fridman
Journal:  Int Rev Immunol       Date:  1986-07       Impact factor: 5.311

Review 5.  Structure and function of human and murine receptors for IgG.

Authors:  J C Unkeless; E Scigliano; V H Freedman
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

6.  Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.

Authors:  N C Sun; D D Ho; C R Sun; R S Liou; W Gordon; M S Fung; X L Li; R C Ting; T H Lee; N T Chang
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120.

Authors:  C Thiriart; M Francotte; J Cohen; C Collignon; A Delers; S Kummert; C Molitor; D Gilles; P Roelants; F van Wijnendaele
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

8.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

Authors:  M R Posner; T Hideshima; T Cannon; M Mukherjee; K H Mayer; R A Byrn
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

9.  Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.

Authors:  D D Ho; J C Kaplan; I E Rackauskas; M E Gurney
Journal:  Science       Date:  1988-02-26       Impact factor: 47.728

Review 10.  Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.

Authors:  J G van de Winkel; P J Capel
Journal:  Immunol Today       Date:  1993-05
View more
  6 in total

1.  Unique morphological alterations of the HTLV-I transformed C8166 cells by infection with HIV-1.

Authors:  J Ongrádi; H M Laird; J F Szilágyi; A Horváth; M Bendinelli
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.

Authors:  Lautaro G Perez; Matthew R Costa; Christopher A Todd; Barton F Haynes; David C Montefiori
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

3.  Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages.

Authors:  Stefania Varchetta; Paolo Lusso; Kelly Hudspeth; Joanna Mikulak; Dalila Mele; Stefania Paolucci; Raffaello Cimbro; Mauro Malnati; Agostino Riva; Renato Maserati; Mario U Mondelli; Domenico Mavilio
Journal:  Retrovirology       Date:  2013-12-13       Impact factor: 4.602

4.  Fcγ Receptor Type I (CD64)-Mediated Impairment of the Capacity of Dendritic Cells to Activate Specific CD8 T Cells by IgG-opsonized Friend Virus.

Authors:  Zoltán Bánki; Roland Werner; Lydia Riepler; Annika Rössler; Brigitte Müllauer; Verena Hegen; Wibke Bayer; J Sjef Verbeek; Ulf Dittmer; Heribert Stoiber
Journal:  Viruses       Date:  2019-02-08       Impact factor: 5.048

5.  Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.

Authors:  Yuru Shang; Xianbin Zhang; Lili Lu; Ke Jiang; Mathias Krohn; Stephanie Matschos; Christina Susanne Mullins; Brigitte Vollmar; Dietmar Zechner; Peng Gong; Michael Linnebacher
Journal:  Br J Cancer       Date:  2021-02-09       Impact factor: 7.640

6.  CD32 Expression is not Associated to HIV-DNA content in CD4 cell subsets of individuals with Different Levels of HIV Control.

Authors:  Marcial García; María Angeles Navarrete-Muñoz; José M Ligos; Alfonso Cabello; Clara Restrepo; Juan Carlos López-Bernaldo; Francisco Javier de la Hera; Carlos Barros; María Montoya; Manuel Fernández-Guerrero; Vicente Estrada; Miguel Górgolas; José M Benito; Norma Rallón
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.